NCT04693377 2026-04-15
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
M.D. Anderson Cancer Center
Phase NA Recruiting
Clinical Trials
29 trialsNCT07126158 2026-04-15
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Washington University School of Medicine
Phase 2 Recruiting
NCT07293468 2026-04-09
BIIRTH
Tuen Mun Hospital
Phase 2/3 Recruiting
NCT07166406 2026-04-08
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NRG Oncology
Phase 3 Recruiting
NCT06218420 2026-03-03
TRANSRAD-01
Assistance Publique - Hôpitaux de Paris
Phase 2 Recruiting
NCT07150546 2026-03-02
Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
Emory University
Phase 1 Recruiting
NCT05488522 2026-02-20
SBRT With Atezo/Bev for HCC
Abramson Cancer Center at Penn Medicine
Phase 1 Recruiting
NCT07305428 2025-12-26
Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study
The University of Hong Kong
Phase NA Recruiting
NCT07297004 2025-12-22
Stereotactic Body Radiation Therapy for Unresectable Locally Recurrent Rectal Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Recruiting
NCT03704662 2025-10-08
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
Medical College of Wisconsin
Phase NA Recruiting
NCT03492671 2025-10-02
Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
Loma Linda University
Phase 2 Recruiting
NCT06843551 2025-08-14
EMPIRE
University of Miami
Phase 2 Recruiting
NCT06691425 2025-08-08
TORPEDO
Cancer Research Antwerp
Phase NA Recruiting
NCT06493734 2025-07-15
STRONG II
Erasmus Medical Center
Phase NA Recruiting
NCT06356584 2025-06-26
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT06130826 2025-05-30
Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT06794086 2025-05-13
SPARKLE-L
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Recruiting
NCT03895359 2025-03-11
TACE
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 3 Recruiting
NCT05596630 2025-02-10
Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase NA Recruiting
NCT06767007 2025-01-22
SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Recruiting
NCT06766643 2025-01-09
Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06725121 2024-12-16
MacroTrans
University Health Network, Toronto
Phase 1/2 Recruiting
NCT02185443 2024-12-09
Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases
University of Sao Paulo
Phase 2 Recruiting
NCT06313190 2024-11-18
HSBRT2402
Sun Yat-sen University
Phase 2 Recruiting
NCT06664996 2024-10-30
Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT
West China Hospital
Phase 2 Recruiting
NCT04498767 2024-08-26
OligoRARE
European Organisation for Research and Treatment of Cancer - EORTC
Phase NA Recruiting
NCT06185556 2024-08-23
COLDFIRE-III
Amsterdam UMC, location VUmc
Phase 2/3 Recruiting
NCT06261125 2024-03-12
HSBRT2401
Sun Yat-sen University
Phase 2 Recruiting
NCT05679583 2023-01-11
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
Yonsei University
Phase 2 Recruiting